{Reference Type}: Case Reports
{Title}: A case of latanoprost-induced diffuse facial skin hyperpigmentation.
{Author}: Kim HY;Lee SK;Lee JH;Suh JH;Kim MS;Lee UH;
{Journal}: J Cosmet Dermatol
{Volume}: 18
{Issue}: 6
{Year}: Dec 2019
{Factor}: 2.189
{DOI}: 10.1111/jocd.12920
{Abstract}: <B>BACKGROUND: </B>Latanoprost is a prostaglandin F2α analogue, which has been used as a first-line drug for open-angle glaucoma. Common side effects of latanoprost include hyperpigmentation. While it usually occurs on irides or periocular skin, diffuse facial hyperpigmentation is rarely reported.<BR><B>METHODS: </B>A 71-year-old woman was presented with diffuse gray-brown colored maculopatches on her face. The symptom appeared 1 week after she started to use latanoprost eye drops for glaucoma. Biopsy specimen revealed vacuolar degeneration of dermo-epidermal junction and pigment incontinence in dermis.<BR><B>OBJECTIVE: </B>The aim of this paper is to introduce a rare adverse effect of latanoprost and effective way of treatment.<BR><B>METHODS: </B>We stopped her from using latanoprost. She was also treated with 532-nm potassium titanyl phosphate laser and low-fluence 1064-nm Q-switched Nd:YAG laser, while using topical agents.<BR><B>RESULTS: </B>After 10 weeks, we observed hyperpigmentation of her face was effectively and safely treated. The patient was satisfied with the result.<BR><B>CONCLUSIONS: </B>Diffuse facial pigmentation could be one of the latanoprost-induced adverse effects and the laser treatments with topical agents we used can make it improve faster.